Characterization of resistance to newer antimicrobials among carbapenem-resistant Klebsiella pneumoniae in the post-acute-care setting

Helen L Zhang; Kyle J Gontjes; Jennifer H Han; Kevin Alby; Zena Lapp; Evan Snitkin; Ellie J C Goldstein; Sean Muldoon; Pam Tolomeo; Ebbing Lautenbach

doi:10.1017/ice.2022.185

Characterization of resistance to newer antimicrobials among carbapenem-resistant Klebsiella pneumoniae in the post-acute-care setting

Infect Control Hosp Epidemiol. 2023 Jul;44(7):1159-1162. doi: 10.1017/ice.2022.185. Epub 2022 Jul 28.

Authors

Helen L Zhang^{1

2}, Kyle J Gontjes³, Jennifer H Han^{1

2

4}, Kevin Alby⁵, Zena Lapp⁶, Evan Snitkin³, Ellie J C Goldstein^{7

8}, Sean Muldoon⁹, Pam Tolomeo^{2

4}, Ebbing Lautenbach^{1

2

4}

Affiliations

¹ Division of Infectious Diseases, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
² Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania.
³ Department of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, Michigan.
⁴ Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania Perelman School of Medicine, Pennsylvania.
⁵ Department of Pathology and Lab Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
⁶ Department of Computational Medicine and Bioinformatics, University of Michigan Medical School, Ann Arbor, Michigan.
⁷ R.M. Alden Research Laboratory, Santa Monica, California.
⁸ Department of Medicine, David Geffen School of Medicine at the University of California, Los Angeles, California.
⁹ ScionHealth, Louisville, Kentucky.

Abstract

We assessed susceptibility patterns to newer antimicrobial agents among clinical carbapenem-resistant Klebsiella pneumoniae (CRKP) isolates from patients in long-term acute-care hospitals (LTACHs) from 2014 to 2015. Meropenem-vaborbactam and imipenem-relebactam nonsusceptibility were observed among 9.9% and 9.1% of isolates, respectively. Nonsusceptibility to ceftazidime-avibactam (1.1%) and plazomicin (0.8%) were uncommon.

MeSH terms

Anti-Bacterial Agents / pharmacology
Anti-Bacterial Agents / therapeutic use
Ceftazidime*
Drug Combinations
Humans
Klebsiella pneumoniae*
Microbial Sensitivity Tests
beta-Lactamases

Substances

Ceftazidime
Anti-Bacterial Agents
Drug Combinations
beta-Lactamases

Abstract

MeSH terms

Substances

Grants and funding